Distributed manufacturing of cell culture products offers a path to significantly lower emissions in pharmaceutical production. By moving production closer to the point of use, companies can reduce the end to end carbon footprint of bioprocessing by up to two thirds. This shift focuses on optimizing the supply chain to eliminate unnecessary transport and logistics emissions. It highlights the role of localized production in making the drug manufacturing process more sustainable.
Log in to join the discussion
Cutting emissions by two thirds sounds great, but I want to see the actual numbers on the equipment. Moving production to the point of use usually means more small sites to maintain. The energy cost of running ten small HVAC systems is often higher than one big one.
Exactly. Distributed manufacturing shifts the load. If these point of use sites are in areas with dirty grids, the carbon savings from shipping are just traded for higher operational emissions. Does the data account for the local grid mix?
The real hurdle here is regulation. Pharma is built on centralized quality control and strict site certifications. Shifting to distributed manufacturing requires a total rethink of how regulators validate a process across multiple locations.
